News: Portfolio 2007
Safeguard Scientifics Leads $8.7 Million Series B Financing For Cellumen, Inc.
(continued)
Michael J. Pellini, MD, Vice President of Life Sciences at Safeguard Scientifics, will join Cellumen's Board of Directors.
About Cellumen
Cellumen, Inc. is the Cellular Systems Biology Company. Cellumen focuses on the cell as an integrated and interacting network of genes, proteins and metabolites responsible for normal and abnormal (disease) function. To promote efficient drug discovery and development, the company offers solutions to the dual challenges of efficacy and toxicity. The company's products and services have application in each of the major segments of the pharmaceutical pipeline: drug discovery ("cellular models of disease"), drug development ("cytotoxicity profiling") and clinical trials ("patient sample profiling"). The Cellumen team leverages its experience and expertise in High Content Screening, cell-based assays, advanced reagents and bioinformatics to create high value solutions. http://www.cellumen.com